CIK细胞疗法联合TACE治疗原发性肝癌患者临床疗效观察

doi:10.3969/j.issn.1672-5069.2015.06.020

摘要/Abstract

摘要： 目的探讨细胞因子诱导的杀伤细胞（CIK）免疫治疗联合肝动脉化疗栓塞（TACE）术治疗原发性肝癌患者的临床疗效。方法选择2012年2月~2014年2月间在本院确诊并行TACE术的67例原发性肝癌患者,按是否联合CIK治疗分为联合治疗组（CIK+TACE）32例和对照组（TACE）35例,比较两组患者外周血T淋巴细胞亚群变化、生活质量（QOL）改善、临床疗效、无进展生存期（PFS）等指标。结果在CIK首次回输后7 d,联合治疗组患者外周血CD3⁺、CD4⁺细胞的比例和CD4⁺/CD8⁺比值分别为（70.32±2.36）%、（32.18±2.27）%和（1.15±0.05）,显著高于CIK细胞治疗前水平[（63.56±2.42）%、（30.34±2.05）%和（0.90±0.05）,P<0.05）];CIK细胞治疗后外周血CD8⁺细胞比例为（29.35±2.95）%,显著低于治疗前水平[（33.28±3.14）%,P<0.05];联合治疗组患者生活质量明显改善,治疗前后Karuafsky评分分别为（74.6.±12.5）和[（83.4±14.7）,P<0.05];联合治疗组部分缓解率为53.1%,与对照组42.9%比,无显著性差异（P>0.05）;联合治疗组中位PFS为16个月,显著高于对照组的9.5个月（P<0.05）;CIK治疗后不良反应轻微,对症处理后均恢复正常。结论CIK细胞免疫疗法联合TACE术较单纯TACE术治疗,可以提高肝癌患者的细胞免疫功能,改善原发性肝癌患者的生存质量,延缓肿瘤进展。

关键词: 原发性肝癌, 肝动脉化疗栓塞, 细胞因子诱导的杀伤细胞, 治疗

Abstract: Objective To investigate the clinical efficacy of cytokine-induced killer cells（CIK） combined with transcatheter arterial chemoembolization（TACE） for patients with primary liver cancer. Methods A total of 67 patients with primary liver cancer were enrolled in Daping hospital from February 2012 to February 2014. According to therapy choice,the patients were divided into combination treatment group（n=32,treated with CIK plus TACE） and control group（n=35,treated with TACE alone）. The peripheral T-lymphocyte subsets alterations, quality of life（QOL）,clinical efficacy and the progression-free-survival（PFS） after treatment were compared between the two groups. Results The proportions of CD3⁺T lymphocytes,CD4⁺T lymphocytes and CD4⁺/CD8⁺ ratio in peripheral blood were significantly increased 7 days after CIK treatment in combination therapy group [（70.32±2.36）% vs.（63.56±2.42）%,（32.18±2.27）% vs.（30.34±2.05）%,and（1.15±0.05） vs.（0.90±0.05）, respectively,P<0.05 for all];The proportion of CD8⁺T lymphocytes was significantly decreased in combination treatment group[（29.35±2.95）% vs.（33.28±3.14）%,P<0.05];Partial remission rate was higher in combination treatment group as compared with that in control group,but with no statistical difference（53.1% vs. 42.9%,P>0.05）;The median PFS was significantly different between the two groups（16 months vs. 9.5 months,P<0.05）;Adverse effects in combination treatment group were mild,and the symptoms disappeared after managements. Conclusions CIK combined with TACE therapy can significantly increase the cell immune function in patients with primary liver cancer than TACE therapy alone. it can improve the QOL and slow the progress of liver cancer in patients with hepatocellular carcinoma.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Cytokine-induced killer cells, Therapy

张艳梅，崔红利，颜綦先，宋娇，何静，孙志亚，徐祥，陈东风，陈舜贤. CIK细胞疗法联合TACE治疗原发性肝癌患者临床疗效观察[J]. 实用肝脏病杂志, 2015, 18(6): 647-650.

Zhang Yanmei， Cui Hongli， Yan Qixian， et al.. Clinical evaluation of cytokine-induced killer cell therapy combined with transcatheter arterial chemoembolization for patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 647-650.

参考文献

[1] Ferenci P,Fried M,Labrecque D,et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma（HCC）:a global perspective. J Gastrointest Liver,2010,19（3）:311-317.
[2] Mesiano G,Todorovic M,Gammatoni L,et al. Cytokine-induced killer（CIK） cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opinion Biol Ther,2012,12（6）:673-684.
[3] Llovet JM,Bruix J. Molecular targeted therapies in hepatocellular carcinoma .Hepatology,2008,48（4）：1312-1327.
[4] 杨秉辉,丛文铭,周晓军,等. 原发性肝癌规范化诊治的专家共识.实用肝脏病杂志. 2009,12（5）：321-328.
[5] Kim MN,Kim BK,Han KH,et al. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol,2015,9（3）:335-348.
[6] Spangenberg HC,Thimme R,Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis,2006,26（4）:385-390.
[7] Firouznia K,Ghanaati H,Alavian SM,et al. Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Hepat Mon,2014,14（12）: e25792.
[8] Gadaleta CD,Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumors: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol,2011,80（1）:40-53.
[9] Imai N,Ishigami M,Ishizu Y,et al. Transarterial chemoembolization for hepatocellular carcinoma:A review of techniques. World J Hepatol,2014,6（12）:844-850.
[10] Cheng HY,Wang XY,Zhao GL,et al. Imaging findings and
transcatheter arterial chemoembolization of hepatic malignancy with right atrial embolus in 46 patients. World J Gastroenterol,2008,14（22）:3563-3568.
[11] Greten TF,Wang XW,Korangy F. Current concepts of immune based treatments for patients with HCC:from basic science to novel treatment approaches. Gut,2015,64（5）:842-848.
[12] Grivennikov SI,Greten FR,Karin M. Immunity,inflammation, and cancer. Cell,2010,140（6）:883-899.
[13] Breous E,Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol,2011,54（4）:830-834.
[14] 佟立权,赵海峰,尤立光,等. TACE术联合自体CIK细胞治疗原发性肝癌的临床研究. 中国普通外科杂志,2013,5（7）:876-879.
[15] Cui JW,Wang NY,Zhao HJ,et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer,2014,134（2）:342-351.
[16] Huang ZM,Li W,Gao F,et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother,2013,36（5）:287-293.
[17] Yu X,Zhao H,Liu L,et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol,2014,34（2）:194-203.
[18] Kim HM,Lim J,Yoon YD,et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol,2007,7（13）:1793-801.
[19] 王春花,胡冰. CIK免疫治疗对肿瘤患者生活质量影响的观察. 安徽医药,2013,17（3）:406-408.
[20] Hui D,Qiang L,Jian W,et al. A randomized,controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis, 2009, 41（1）:36-41.